Overview

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GATE-101 in normal human volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Gate Neurosciences, Inc